Guardant Health(GH)

PALO ALTO, CADiagnostics5 H-1B visas (FY2023)

Focus: Guardant Health is a public diagnostics company headquartered in Palo Alto, CA, specializing in liquid biopsy and cell-free DNA testing for cancer detection and monitoring. With 1,001-5,000 employees, it operates as a scaled, publicly traded diagnostics platform.

Profile data last refreshed 10h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Guardant Health

AI assessmentNot Hiring

No open roles listed right now. Follow Guardant Health to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$564M

Key Products

Guardant360

Non-Small Cell Lung Cancer, Advanced Breast Cancer, Metastatic Disease

Growth

Flagship liquid biopsy panel deployed across multiple solid tumor indications with active clinical utility studies and registry outcomes tracking.

Guardant Shield

Colorectal Cancer Screening

Help build intelligence for Guardant Health

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

High R&D intensity (65%) indicates substantial investment in innovation and scientific talent development across oncology diagnostics
Public company with $564M FY2025 revenue and strong cash position ($1.1B) provides career stability and resources for advancement
Broad pipeline of 22 programs across multiple cancer indications (lung, colorectal, breast, pancreatic) offers diverse technical and clinical project exposure

Watch Out For

Company is unprofitable (−$479M net loss FY2025, −$655M FY2024) despite revenue growth, signaling aggressive spending or pricing pressure in diagnostics
Limited active hiring visible (0 active job postings listed) may indicate recruitment freeze or tight near-term headcount planning

Generated by Claude from Guardant Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Blood-based CRC screening test positioned to capture early detection market; represents expansion from therapeutic monitoring to preventive screening.

Guardant Reveal

Bladder Carcinoma

Growth

Emerging organ-specific liquid biopsy platform targeting underserved bladder cancer detection and monitoring.

Pipeline & Clinical Trials

Biospecimen Collection

Colorectal Carcinoma

N/A

Clinical Trials (1)

NCT05716477Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

N/A

Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT03746262Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

N/A

Comprehensive liquid molecular panel test

Stage III Solid Tumors

N/A

Clinical Trials (1)

NCT05703243Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")

N/A

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT03791034Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

N/A

Screening Reminder

Colorectal Cancer

N/A

Clinical Trials (1)

NCT07436637Guardant Shield Colorectal Cancer Screening